Get the Stockscreener App
1.405
4.73%
-0.075
Nyxoah Sa stock is traded at $1.405, with a volume of 55,063.
It is down -4.73% in the last 24 hours and down -11.88% over the past month.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
See More
Previous Close:
$1.48
Open:
$1.46
24h Volume:
55,063
Relative Volume:
0.17
Market Cap:
$143.09M
Revenue:
$17.85M
Net Income/Loss:
$-96.93M
P/E Ratio:
-0.568
EPS:
-2.4735
Net Cash Flow:
$-88.29M
1W Performance:
-8.44%
1M Performance:
-11.88%
6M Performance:
-54.22%
1Y Performance:
-71.97%
1-Day Range:
$1.40
$1.46
1-Week Range:
$1.40
$1.58
52-Week Range:
$1.26
$6.8745
Nyxoah Sa Stock (NYXH) Company Profile
Name
Nyxoah Sa
Sector
Industry
Phone
-
Address
-
Compare NYXH vs ISRG, BDX, RMD, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
1.405 | 156.83M | 17.85M | -96.93M | -88.29M | -2.4735 |
ISRG
Intuitive Surgical Inc
|
399.64 | 130.41B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
181.71 | 48.44B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
224.58 | 31.49B | 5.54B | 1.52B | 1.74B | 10.37 |
ALC
Alcon Inc
|
65.48 | 31.92B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
33.99 | 28.54B | 29.14B | 1.07B | 1.05B | 1.1956 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-23 | Initiated | H.C. Wainwright | Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Apr-21-22 | Initiated | Oppenheimer | Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Peer Perform |
| Dec-21-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-28-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Nyxoah Sa Stock (NYXH) Latest News
Nyxoah (NYXH) Begins BREATHE Study. Can Real-World Evidence Drive Genio Adoption? - Yahoo Finance
Nyxoah SA Actuals & Estimates (HAM:5YI) - TradingView
Gross profit of Nyxoah SA – HAM:5YI - TradingView
Price to book ratio of Nyxoah SA – HAM:5YI - TradingView
Nyxoah Begins U.S. Post-Approval Study of Genio Sleep Apnea Implant - finance.biggo.com
Cash per share of Nyxoah SA – HAM:5YI - TradingView
Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial - Yahoo Finance
Nyxoah implants first patient in BREATHE study of Genio - Yahoo
symbol__ Stock Quote Price and Forecast - CNN
Nyxoah Launches Major U.S. Post-Approval Study for Genio Sleep Apnea Device - TipRanks
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System - GlobeNewswire
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
Nyxoah SA (NYXH) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cantor Fitzgerald reiterates Nyxoah stock rating on trial success By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Nyxoah stock rating on trial success - Investing.com
Nyxoah stock rises on pivotal trial win for Genio (NYXH:NASDAQ) - Seeking Alpha
Nyxoah stock surges as sleep apnea study hits endpoints By Investing.com - Investing.com India
NYXH Jumps As ACCCESS Trial Data Reset The Trading Map - timothysykes.com
NYXH Stock Jumps As ACCCESS Trial De‑Risks Sleep Apnea Bet - StocksToTrade
NYXH Stock Pops As ACCCESS Trial Data Fuels Breakout Hopes - timothysykes.com
NYXH Stock Jumps As ACCCESS Trial De-Risks U.S. Growth Story - StocksToTrade
87.7% improved on a measure of oxygen drops during sleep. No device-related serious adverse events were reported. - Stock Titan
Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary - GlobeNewswire
Nyxoah SA (NYXH) Stock Price & News - Syfe
Information on the total number of voting rights and shares - GlobeNewswire
Nyxoah (NYXH) Results Versus Estimates: The Available Earnings Metric Delivers a Miss in the Current Update; Market Reaction: The Share Price Sheds 2.74% in the Current UpdateEarnings Power Value - vinanet.vn
Nyxoah (NYXH) Latest: Falls 2.74% to $1.60 in Latest Trading; Price Context: the Current Price Sits Inside the Supplied Technical Range at the CloseIndex Put Call - vinanet.vn
Cantor Fitzgerald cuts Nyxoah stock price target on valuation By Investing.com - Investing.com Nigeria
Cantor Fitzgerald cuts Nyxoah stock price target on valuation - Investing.com
Cantor Fitzgerald Issues Pessimistic Forecast for Nyxoah (NASDAQ:NYXH) Stock Price - MarketBeat
NYXH Q2 2026 Earnings: EPS Miss of 46.48% Overshadowed by 2.53% Share GainCapex Guidance - vinanet.vn
Understanding Momentum Shifts in (NYXH) - Stock Traders Daily
Nyxoah (NASDAQ: NYXH) investors report 11.0M-share, 9.9% beneficial stake - Stock Titan
Nyxoah (NYXH) Q2 2026 Earnings: Wider-than-Expected Loss Flags Cost PressuresQuarterly Profit Report - dars.gov.et
Nyxoah SA (EBR:NYXH) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - webull.com
Wall Street Zen Downgrades Nyxoah (NASDAQ:NYXH) to Sell - MarketBeat
A Quick Look at Today's Ratings for Nyxoah SA(NYXH.US), With a Forecast Between $2.31 to $6 - Moomoo
Nyxoah (NASDAQ:NYXH) Releases Earnings Results, Misses Expectations By $0.20 EPS - MarketBeat
Oppenheimer Adjusts Price Target on Nyxoah to $4 From $13, Maintains Outperform Rating - marketscreener.com
Nyxoah SA Stock 12‑Month Price Target Cut to $6, Implies 326% Upside - TradingView
Nyxoah SA Revenue Breakdown – EURONEXT:NYXH - TradingView
Piper Sandler Maintains Nyxoah SA(NYXH.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
Nyxoah Q2 Earnings Call Highlights - MarketBeat
Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results - The Manila Times
Nyxoah SA (NYXH) (Q2 2026) Earnings Call Highlights: US Revenue Surges 22% Sequentially, $110M ... - Yahoo Finance
Nyxoah SA reports results for the quarter ended June 30Earnings Summary - TradingView
Nyxoah SA (NYXHB.XD) Q2 FY2026 earnings call transcript - Yahoo Finance
NYXH: Q2 2026 revenue surged 21% sequentially, with strong U.S. growth and robust outlook - TradingView
Earnings To Watch: Nyxoah SA (XBRU:NYXH) Q2 2026 -- GF Value Sees 5209% Upside - GuruFocus
Avoiding Lag: Real-Time Signals in (NYXH) Movement - Stock Traders Daily
Nyxoah SA (NYXH) Holds at $1.45 as Sleep Apnea MedTech Stock Tests Key Support ZoneOrder Block - dars.gov.et
Nyxoah Sa Stock (NYXH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):